Kiromic Biopharma, Inc. Increase (Decrease) in Interest Payable, Net
Kiromic Biopharma, Inc. reported Increase (Decrease) in Interest Payable, Net of $3.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2024-11-08
- Kiromic Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2024-09-30 was $3.83M, a 787.70% increase year-over-year.
- Kiromic Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2024-06-30 was -$1.90M, a 695.61% decline year-over-year.
- Kiromic Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2024-03-31 was $1.07M, a 148.26% increase year-over-year.
- Kiromic Biopharma, Inc. increase (decrease) in interest payable, net for the quarter ending 2023-12-31 was $614.80K.
- Kiromic Biopharma, Inc. increase (decrease) in interest payable, net for fiscal 2023 was $1.80M, a 1163.76% increase from fiscal 2022.
- Kiromic Biopharma, Inc. increase (decrease) in interest payable, net for fiscal 2022 was $142.10K.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 3 month as first filed | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 6 month as first filed | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 9 month as first filed | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | $3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $1.93M derived: sum of 2 quarters · filed 2024-11-08 | $3.00M 10-Q · filed 2024-11-08 | $3.61M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2024-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$830.00K 10-Q · filed 2024-08-09 | -$215.20K derived: sum of 3 quarters · filed 2024-08-09 | $215.80K derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2024-03-31 | $1.07M 10-Q · filed 2024-05-10 | $1.68M derived: sum of 2 quarters · filed 2024-05-10 | $2.12M derived: sum of 3 quarters · filed 2024-11-08 | $2.43M derived: sum of 4 quarters · filed 2024-11-08 | |||
| 2023-12-31 | $614.80K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.05M derived: sum of 2 quarters · filed 2024-11-08 | $1.36M derived: sum of 3 quarters · filed 2024-11-08 | $1.80M 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $431.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $750.00K derived: sum of 2 quarters · filed 2024-11-08 | $1.18M 10-Q · filed 2024-11-08 | $1.18M 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $750.00K 10-Q · filed 2024-08-09 | $749.80K 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $431.00K 10-Q · filed 2024-05-10 | $431.40K 10-Q · filed 2023-05-15 | |||||
| 2022-12-31 | $142.10K 10-K · filed 2024-03-19 |